Program
CAR-T
Its studies are mostly in Connective Tissue Diseases · Colorectal Neoplasms, led by Guangzhou Bio-gene Technology.
Furthest: no phase, since Aug 26, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Bio-gene Technology | 30 open or running | no phasesince Aug 26, 2025 | Aug 26, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2025First studies: 3 no phase studiesFirst studyNCT07152236, NCT07152223, NCT07152210
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07152236Solid Tumors · China | – | Withdrawn | Mar 2, 2026 | 0 |
| NCT07152223Connective Tissue Diseases · China | – | Withdrawn | Mar 2, 2026 | 0 |
| NCT07152210Colorectal Neoplasms · China | – | Withdrawn | Mar 2, 2026 | 0 |
How it is read
Names in the registry
- “CAR-T”, 3 entries
Conditions, from the studies’ own filings
- Connective Tissue Diseases, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.